A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 delivery for myocardial infarction REduction) study

Publication | Closed Access

DOI

113

Citations

References

2003

Year

Stephen L. Kopecky, Ronnier J. Aviles, Malcolm R. Bell, Joseph K. Lobl, Diane Tipping, Gregg Frommell, Karen E. Ramsey, Anne E. Holland, Mark Midei, Abnash C. Jain,

American Heart Journal

ThrombosisPercutaneous Coronary InterventionAmp579 DeliveryCardiovascular DiseaseAtherosclerosisCardiovascular PharmacologyAdenosine AgonistSurgeryPharmacotherapyDose-ranging StudyMedicineCardiologyCoronary Artery DiseaseAcute Myocardial InfarctionMyocardial Infarction